Role of RNA binding protein HuR in ductal carcinoma in situ of the breast

Journal of Pathology

Volumn 224, Issue 4, 2011, Pages 529-539

  Heinonen, Mira ^a,b   Hemmes, Annabrita ^a,b   Salmenkivi, Kaisa ^a   Abdelmohsen, Kotb ^c   Vilén, Suvi Tuuli ^b   Laakso, Marko ^b,d   Leidenius, Marjut ^e   Salo, Tuula ^f   Hautaniemi, Sampsa ^b,d   Gorospe, Myriam ^c   Heikkilä, Päivi ^a   Haglund, Caj ^a,e   Ristimäki, Ari ^a,b  

^a UNIVERSITY OF HELSINKI   (Finland)

^b UNIVERSITY OF HELSINKI   (Finland)

^c NATIONAL INSTITUTES OF HEALTH   (United States)

^d UNIVERSITY OF HELSINKI   (Finland)

^e HELSINKI UNIVERSITY CENTRAL HOSPITAL   (Finland)

^f UNIVERSITY OF OULU   (Finland)

Author keywords

atypical ductal hyperplasia; breast cancer; carcinogenesis; Drosophila embryonic lethal abnormal vision protein; ductal carcinoma in situ; HuR; pre malignant

Indexed keywords

CONNECTIVE TISSUE GROWTH FACTOR; HUR PROTEIN; PROGESTERONE RECEPTOR; RNA BINDING PROTEIN;

ADULT; AGED; ANCHORAGE INDEPENDENT GROWTH; ARTICLE; BREAST CARCINOMA; CANCER CELL CULTURE; CANCER GRADING; CANCER INVASION; CARCINOGENESIS; CARCINOMA IN SITU; CELL DEATH; CELL IMMORTALIZATION; CYTOPLASM; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; PROTEIN FUNCTION;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTIGENS, SURFACE; BREAST; BREAST NEOPLASMS; CARCINOMA, INTRADUCTAL, NONINFILTRATING; CELL TRANSFORMATION, NEOPLASTIC; DISEASE PROGRESSION; EPITHELIAL CELLS; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; GENE REGULATORY NETWORKS; GENE SILENCING; HUMANS; HYPERPLASIA; MIDDLE AGED; NEOPLASM PROTEINS; PRECANCEROUS CONDITIONS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA-BINDING PROTEINS; TUMOR CELLS, CULTURED; YOUNG ADULT;

EID: 79959957496     PISSN: 00223417     EISSN: 10969896     Source Type: Journal    
DOI: 10.1002/path.2889     Document Type: Article

References (50)

1. Ma WJ, Cheng S, Campbell C, et al., Cloning and characterization of HuR, a ubiquitously expressed Elav-like protein. J Biol Chem 1996; 271: 8144-8151. (Pubitemid 26108641)
2. Ma WJ, Furneaux H,. Localization of the human HuR gene to chromosome 19p13.2. Hum Genet 1997; 99: 32-33. (Pubitemid 26419850)
3. Brennan CM, Steitz JA,. HuR and mRNA stability. Cell Mol Life Sci 2001; 58: 266-277. (Pubitemid 32217358)
4. Lopez de Silanes I, Zhan M, Lal A, et al., Identification of a target RNA motif for RNA-binding protein HuR. Proc Natl Acad Sci USA 2004; 101: 2987-2992. (Pubitemid 38327723)
5. Gallouzi IE, Steitz JA,. Delineation of mRNA export pathways by the use of cell-permeable peptides. Science 2001; 294: 1895-1901. (Pubitemid 33101580)
6. Erkinheimo TL, Lassus H, Sivula A, et al., Cytoplasmic HuR expression correlates with poor outcome and with cyclooxygenase 2 expression in serous ovarian carcinoma. Cancer Res 2003; 63: 7591-7594. (Pubitemid 37466678)
7. Denkert C, Weichert W, Pest S, et al., Overexpression of the embryonic-lethal abnormal vision-like protein HuR in ovarian carcinoma is a prognostic factor and is associated with increased cyclooxygenase 2 expression. Cancer Res 2004; 64: 189-195. (Pubitemid 38114097)
8. Heinonen M, Bono P, Narko K, et al., Cytoplasmic HuR expression is a prognostic factor in invasive ductal breast carcinoma. Cancer Res 2005; 65: 2157-2161. (Pubitemid 40490122)
9. Mrena J, Wiksten JP, Thiel A, et al., Cyclooxygenase-2 is an independent prognostic factor in gastric cancer and its expression is regulated by the messenger RNA stability factor HuR. Clin Cancer Res 2005; 11: 7362-7368. (Pubitemid 41507695)
10. Heinonen M, Fagerholm R, Aaltonen K, et al., Prognostic role of HuR in hereditary breast cancer. Clin Cancer Res 2007; 13: 6959-6963. (Pubitemid 350276875)
11. Yoo PS, Sullivan CA, Kiang S, et al., Tissue microarray analysis of 560 patients with colorectal adenocarcinoma: high expression of HuR predicts poor survival. Ann Surg Oncol 2009; 16: 200-207.
12. Hostetter C, Licata LA, Witkiewicz A, et al., Cytoplasmic accumulation of the RNA binding protein HuR is central to tamoxifen resistance in estrogen receptor positive breast cancer cells. Cancer Biol Ther 2008; 7: 1496-1506.
13. Tavassoli FA, Devilee P,. World Health Organization Classification of Tumours. Pathology and Genetics of Tumours of the Breast and Female Genital Organs. IARC Press: Lyon, 2003; 63-73.
14. Leidenius M, Salmenkivi K, von Smitten K, et al., Tumour-positive sentinel node findings in patients with ductal carcinoma in situ. J Surg Oncol 2006; 94: 380-384. (Pubitemid 44465341)
15. Novak P, Jensen TJ, Garbe JC, et al., Stepwise DNA methylation changes are linked to escape from defined proliferation barriers and mammary epithelial cell immortalization. Cancer Res 2009; 69: 5251-5258.
16. Nurmenniemi S, Sinikumpu T, Alahuhta I, et al., A novel organotypic model mimics the tumor microenvironment. Am J Pathol 2009; 175: 1281-1291.
17. Lal A, Mazan-Mamczarz K, Kawai T, et al., Concurrent versus individual binding of HuR and AUF1 to common labile target mRNAs. EMBO J 2004; 23: 3092-3102. (Pubitemid 39093603)
18. Pierce JH, Arnstein P, DiMarco E, et al., Oncogenic potential of erbB-2 in human mammary epithelial cells. Oncogene 1991; 6: 1189-1194. (Pubitemid 21924207)
19. Abdelmohsen K, Gorospe M,. Posttranscriptional regulation of cancer traits by HuR. Wiley Interdiscipl Rev RNA 2010; 1: 214-229.
20. Scott GK, Marx C, Berger CE, et al., Destabilization of ERBB2 transcripts by targeting 3a untranslated region messenger RNA-associated HuR and histone deacetylase-6. Mol Cancer Res 2008; 6: 1250-1258.
21. Al-Ahmadi W, Al-Ghamdi M, Al-Haj L, et al., Alternative polyadenylation variants of the RNA binding protein, HuR: abundance, role of AU-rich elements and auto-regulation. Nucleic Acids Res 2009; 37: 3612-3624.
22. Laakso M, Hautaniemi S,. Integrative platform to translate gene sets to networks. Bioinformatics 2010; 26: 1802-1803.
23. Karipcin FS, Ensari TA, Kayisli UA, et al., The mRNA-binding protein HuR is regulated in the menstrual cycle and repressed in ectopic endometrium. Reprod Sci 2011; 18: 145-155.
24. Denkert C, Weichert W, Winzer KJ, et al., Expression of the ELAV-like protein HuR is associated with higher tumor grade and increased cyclooxygenase-2 expression in human breast carcinoma. Clin Cancer Res 2004; 10: 5580-5586. (Pubitemid 39100499)
25. Woo HH, Zhou Y, Yi X, et al., Regulation of non-AU-rich element containing c-fms proto-oncogene expression by HuR in breast cancer. Oncogene 2009; 28: 1176-1186.
26. Mokbel K, Cutuli B,. Heterogeneity of ductal carcinoma in situ and its effects on management. Lancet Oncol 2006; 7: 756-765. (Pubitemid 44283669)
27. Saunus JM, French JD, Edwards SL, et al., Posttranscriptional regulation of the breast cancer susceptibility gene BRCA1 by the RNA binding protein HuR. Cancer Res 2008; 68: 9469-9478.
28. Hinman MN, Lou H,. Diverse molecular functions of Hu proteins. Cell Mol Life Sci 2008; 65: 3168-3181.
29. Abdelmohsen K, Kuwano Y, Kim HH, et al., Posttranscriptional gene regulation by RNA-binding proteins during oxidative stress: implications for cellular senescence. Biol Chem 2008; 389: 243-255. (Pubitemid 351329020)
30. Mazan-Mamczarz K, Hagner PR, Dai B, et al., Identification of transformation-related pathways in a breast epithelial cell model using a ribonomics approach. Cancer Res 2008; 68: 7730-7735.
31. Woo HH, Yi X, Lamb T, et al., Post-transcriptional suppression of proto-oncogene c-fms expression by vigilin in breast cancer. Mol Cell Biol 2011; 31: 215-225.
32. Xiao L, Rao JN, Zou T, et al., Polyamines regulate the stability of activating transcription factor-2 mRNA through RNA-binding protein HuR in intestinal epithelial cells. Mol Biol Cell 2007; 18: 4579-4590. (Pubitemid 350060183)
33. Chen PS, Wang MY, Wu SN, et al., CTGF enhances the motility of breast cancer cells via an integrin-αvβ3-ERK1/2-dependent S100A4-upregulated pathway. J Cell Sci 2007; 120: 2053-2065.
34. Kotzsch M, Sieuwerts AM, Grosser M, et al., Urokinase receptor splice variant uPAR-del4/5-associated gene expression in breast cancer: identification of rab31 as an independent prognostic factor. Breast Cancer Res Treat 2008; 111: 229-240.
35. Knippen S, Loning T, Muller V, et al., Expression and prognostic value of activating transcription factor 2 (ATF2) and its phosphorylated form in mammary carcinomas. Anticancer Res 2009; 29: 183-189.
36. Mazan-Mamczarz K, Hagner PR, Corl S, et al., Post-transcriptional gene regulation by HuR promotes a more tumorigenic phenotype. Oncogene 2008; 27: 6151-6163.
37. Johnson MR, Wang K, Diasio RB,. Profound dihydropyrimidine dehydrogenase deficiency resulting from a novel compound heterozygote genotype. Clin Cancer Res 2002; 8: 768-774. (Pubitemid 34742106)
38. Kairouz R, Parmar J, Lyons RJ, et al., Hormonal regulation of the Grb14 signal modulator and its role in cell cycle progression of MCF-7 human breast cancer cells. J Cell Physiol 2005; 203: 85-93. (Pubitemid 40328175)
39. Rodrigues-Ferreira S, Di Tommaso A, Dimitrov A, et al., 8p22 MTUS1 gene product ATIP3 is a novel anti-mitotic protein underexpressed in invasive breast carcinoma of poor prognosis. PLos One 2009; 4: e7239.
40. Eiseler T, Döppler H, Yan IK, et al., Protein kinase D1 regulates matrix metalloproteinase expression and inhibits breast cancer cell invasion. Breast Cancer Res 2009; 11: R13.
41. Wang JS, Wang FB, Zhang QG, et al., Enhanced expression of Rab27A gene by breast cancer cells promoting invasiveness and the metastasis potential by secretion of insulin-like growth factor-II. Mol Cancer Res 2008; 6: 372-382.
42. Guo H, Lin Y, Zhang H, et al., Tissue factor pathway inhibitor-2 was repressed by CpG hypermethylation through inhibition of KLF6 binding in highly invasive breast cancer cells. BMC Mol Biol 2007; 8: 110.
43. Kischel P, Waltregny D, Dumont B, et al., Versican overexpression in human breast cancer lesions: known and new isoforms for stromal tumor targeting. Int J Cancer 2010; 126: 640-650.
44. Silverstein MJ, Poller DN, Waisman JR, et al., Prognostic classification of breast ductal carcinoma-in-situ. Lancet 1995; 345: 1154-1157.
45. The Consensus Conference Committee. Consensus Conference on the classification of ductal carcinoma in situ. Cancer 1997; 80: 1798-1802.
46. Leidenius M, Salmenkivi K, von Smitten K, et al., Tumour-positive sentinel node findings in patients with ductal carcinoma in situ. J Surg Oncol 2006; 94: 380-384. (Pubitemid 44465341)
47. Scott GK, Marx C, Berger CE, et al., Destabilization of ERBB2 transcripts by targeting 3' untranslated region messenger RNA associated HuR and histone deacetylase-6. Mol Cancer Res 2008; 6: 1250-1258.
48. Pierce JH, Arnstein P, DiMarco E, et al., Oncogenic potential of erbB-2 in human mammary epithelial cells. Oncogene 1991; 6: 1189-1194. (Pubitemid 21924207)
49. Novak P, Jensen TJ, Garbe JC, et al., Stepwise DNA methylation changes are linked to escape from defined proliferation barriers and mammary epithelial cell immortalization. Cancer Res 2009; 69: 5251-5258.
50. Laakso M, Hautaniemi S,. Integrative platform to translate gene sets to networks. Bioinformatics 2010; 26: 1802-1803.